Bristol-Myers Squibb and Simcere Pharmaceutical have expanded their strategic relationship formed in 2010. The companies have agreed to collaborate in China on the development and commercialisation of the subcutaneous (sc) formulation of BMS' biologic medicine, Orencia (abatacept), for the treatment of rheumatoid arthritis (RA). Orencia sc is already on the market for the treatment of RA in the US, Europe and Japan.
Under the terms of the agreement, Simcere will perform and fund all development and regulatory activities required to obtain market approval for Orencia sc in China, based on a pre-agreed development plan. The companies will share responsibility for commercialising Orencia and will share profits and losses related to Orencia sc in China. Financial terms were not disclosed.
Orencia sc is the third programme in Simcere's R&D collaboration with BMS. The company plans to bring in more late-stage programmes and products already approved outside of China. If successful, not only could Orencia sc bring a new option to Chinese patients with RA, but also it could become BMS' first biologic medicine for the Chinese market. In 2010, BMS and Simcere established an innovative strategic partnership to co-develop BMS-817378, a preclinical small-molecule Met/VEGFr-2 inhibitor for oncology indications, and in 2011, extended the partnership to include co-development of BMS-795311, BMS' preclinical small-molecule cholesteryl ester transfer protein (CETP) inhibitor, intended for use in the prevention of cardiovascular disease.
|Agreement Status:||New||Date Announced:||14 Jun 2013|
|Date Last Reported:||Duration:|
|Est Total Value:||Investment To Date:|
|Agreement Type:||Commercialisation Development|
|Generic / Brand Name:||Orencia abatacept|
|Therapeutic Area:||Antineoplastic and Immunomodulating Agents|